We serve Chemical Name:2-(1H-Imidazol-1-yl)ethanol CAS:1615-14-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(1H-Imidazol-1-yl)ethanol
CAS.NO:1615-14-1
Synonyms:EINECS 216-565-3;MFCD00209980;2-imidazol-1-ylethanol;1H-Imidazole-1-ethanol;2-(1H-Imidazol-1-yl)ethanol;1-(2-Hydroxyethyl)imidazole;1-(2-Hydroxyethyl)-imidazole
Molecular Formula:C5H8N2O
Molecular Weight:112.130
HS Code:2933290090
Physical and Chemical Properties:
Melting point:36-40 °C(lit.)
Boiling point:316.5±25.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.550
PSA:38.05000
Exact Mass:112.063660
LogP:-0.63
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like EINECS 216-565-3 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-(2-Hydroxyethyl)-imidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(1H-Imidazol-1-yl)ethanol Use and application,MFCD00209980 technical grade,usp/ep/jp grade.
Related News: When these modified cells are given back to the patient, they are transported in the bloodstream to the bone marrow where they start to make healthy red blood cells that produce beta-globin. The effects of Zynteglo are expected to last for the patient’s lifetime. 3,3′-((((4,4′-sulfonylbis(benzoyl))bis(azanediyl))bis(2,5-dimethoxy-4,1-phenylene))bis(diazene-2,1-diyl))bis(4-hydroxy-5-(phenylsulfonamido)naphthalene-2,7-disulfonic acid) manufacturers A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The University of Texas Health Science Center at Houston (UTHealth), The University of Texas Medical Branch at Galveston (UTMB Health), the University of Houston, and IGM Biosciences, Inc. (E)-2-(7-hydroperoxy-4-hydroxy-5-(1-oxidaneyl)-11,34,44,53,73-nonaoxidan-3-enyl)-13,24,33,43,53,63-hexaoxine suppliers Inspired by the spirit of Start with Integrity, Succeed through Action,” Innovent’s mission is to develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 1-(5-((4-hydroperoxy-13,24,33,44,53,63-hexaoxin-2-yl)oxy)-13,24,33,43,54,63-hexaoxin-2-yl)-24-trioxidan-2-one vendor & factory.
Established in 2011, Innovent is committed to developing, manufacturing and commercializing high-quality innovative medicines for the treatment of cancer, autoimmune, metabolic and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
Leveraging the platform, the company has built a robust pipeline of 25 valuable assets in the fields of cancer, metabolic, autoimmune disease and other major therapeutic areas, with 5 products – TYVYT® (sintilimab injection), BYVASDA® (bevacizumab biosimilar injection), SULINNO® (adalimumab biosimilar injection), HALPRYZA® (rituximab biosimilar injection) and Pemazyre® (pemigatinib oral inhibitor) – officially approved for marketing, 1 asset’s NDA under NMPA review, sintilimab’s Biologics License Application (BLA) acceptance in the U.S., 5 assets in Phase 3 or pivotal clinical trials, and an additional 14 molecules in clinical studies.
Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners.
Innovent strives to work with many collaborators to help advance China’s biopharmaceutical industry, improve drug availability and enhance the quality of the patients’ lives. For more information, please visit 1-(5-((4-hydroperoxy-13,24,33,44,53,63-hexaoxin-2-yl)oxy)-13,24,33,43,54,63-hexaoxin-2-yl)-24-trioxidan-2-one vendor & factory.
